$GXAI

Gaxos.ai Finalizes Partnership with Byteplus for AI Video Tools

Gaxos.ai has finalized a partnership with Byteplus, which will provide Gaxos.ai with preferred pricing and discounts on ByteDance's advanced AI video generation models for its Art-Gen platform. This collaboration aims to accelerate Gaxos.ai's penetration into the global creator economy by embedding state-of-the-art AI video tools, enhancing content creation, reducing infrastructure costs, and improving scalability. Additionally, Gaxos.ai is collaborating with AWS partner Caylent to develop a real-time sales platform and has launched a $3 million stock offering to fund future growth.

Original reporting
Intellectia AI · Emily J. Thompson
Published Feb 17, 2026, 1:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 17, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GXAI
Bullish
high confidence
Mentioned
$GXAI
Relevance
6/10
AlphAI data visualization · based on Intellectia AI
Decision brief

The 30-second read

$GXAIBullishMed
01

Why it matters

The collaboration with Byteplus and AWS is expected to accelerate product development, reduce costs, and enhance scalability, positively influencing investor sentiment.

02

Market read

The news is highly relevant to AI, digital content, and creator economy sectors, with potential short-term stock movements for GXAI.

03

What to watch

Potential regulatory challenges in AI content creation and competition from larger tech firms could limit GXAI's growth trajectory.

Relevance 6/10Timing: Immediate to short-term (next 1-3 months)

Background

Gaxos.ai is expanding its AI video tools through strategic partnerships to capture a larger share of the creator economy.

Company-level read

Ticker impact

$GXAIBullishHigh confidence
Context

High relevance due to direct involvement in AI video tools and recent partnership news.

Expected impact

Moderate upward movement expected in GXAI stock over the short to medium term.

Evidence & confidence

The collaboration with Byteplus and AWS indicates strategic growth and technological advancement, likely to attract investor interest and improve financial outlook.

Market effects

Positive outlook for AI and creator economy sectors due to increased adoption of AI video tools.

Potentially positive in North America and Asia where creator economies are rapidly growing.

Moderate; impacts primarily technology and digital content sectors.

Counterpoint

The partnership may face execution risks or fail to deliver expected growth, leading to stock underperformance.

Key entities

  • Gaxos.ai

    AI technology company specializing in content creation tools.

  • Byteplus

    AI and data analytics platform, part of ByteDance.

  • ByteDance

    Parent company of Byteplus, a major player in digital content and AI.

  • Caylent

    AWS partner developing real-time sales platform for Gaxos.ai.

Related articles

$GXAILow

GAXOS.AI INC. (GXAI): Gaxos Delivers Record Second-Quarter Revenue, Up 35.8% Sequentially and 1,337% Year over Year

GAXOS.AI INC. (GXAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gaxos Delivers Record Second-Quarter Revenue, Up 35.8% Sequentially and 1,337% Year over Year Revenue growth significantly outpaces advertising expense growth as revenue generated per advertising dollar improves Roseland, NJ / August 12, 2026 – Gaxos.ai Inc. ("Gaxos"

$GXAIMed

GAXOS.AI INC. (GXAI): Completion of Acquisition or Disposition of Assets

GAXOS.AI INC. (GXAI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029589401ex2-1.htm ASSET PURCHASE AGREEMENT BY AND BETWEEN GAXOS.AI INC. AND GAME FOUNDRY AI DATED JUNE 18, 2026 Exhibit 2.1 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “ Agreement ”) entered into as of June 18, 2025 by and among Game Foundry Ai, Inc.,

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.